Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/leonard-hayflick.md — the filesystem corpus, unchanged. Not an edit.
12.4 kB
Revision 1
Revision 2
lines 7–13 → 7–136 unchanged lines not shown
categories: ["people", "longevity"]categories: ["people", "longevity"]tags: ["aging", "cellular senescence", "biogerontology", "cell culture", "vaccines", "hayflick limit"]tags: ["aging", "cellular senescence", "biogerontology", "cell culture", "vaccines", "hayflick limit"]summary: "American microbiologist who showed in 1961 that normal human cells divide a finite number of times in culture, and who argued for fifty years afterwards that aging is not a disease."summary: "American microbiologist who showed in 1961 that normal human cells divide a finite number of times in culture, and who argued for fifty years afterwards that aging is not a disease."updated: "2026-07-28"updated: "2026-10-29"------ ```infobox```infoboxlines 35–45 → 35–4521 unchanged lines not shown
## Overview## Overview Hayflick's position in this wiki is unusual: almost every longevity programme covered here descends inHayflick holds an unusual position in this wiki. Almost every longevity programme covered here descendssome way from his 1961 result, and he rejected almost all of them. He held that aging is not a disease,in some way from his 1961 result, and he rejected almost all of them. He held that aging is not a disease,that it is caused by the accumulation of molecular disorder rather than by a programme that could bethat it is caused by the accumulation of molecular disorder rather than by a programme that could beswitched off, and that no intervention had been shown to slow it in a person. Two of those three claimsswitched off, and that no intervention had been shown to slow it in a person. Two of those three claimsremain the mainstream view. The third — that no such intervention is likely — is where he parted fromremain the mainstream view. The third, that no such intervention is likely, is where he parted fromthe field his work founded.the field his work founded. ## Career## Careerlines 56–62 → 56–6210 unchanged lines not shown
directing the Center for Gerontological Studies at the University of Florida from 1982. He was laterdirecting the Center for Gerontological Studies at the University of Florida from 1982. He was laterprofessor of anatomy at the University of California, San Francisco. He edited *Experimentalprofessor of anatomy at the University of California, San Francisco. He edited *ExperimentalGerontology* for thirteen years, served as president of the Gerontological Society of America inGerontology* for thirteen years, served as president of the Gerontological Society of America in1982–83, and was a founding member of the council of the National Institute on Aging.[^nyt2024]1982-83, and was a founding member of the council of the National Institute on Aging.[^nyt2024] ## The replicative limit## The replicative limit lines 68–75 → 68–755 unchanged lines not shown
Hayflick and Paul Moorhead cultured human fetal fibroblast strains and tracked them through serialHayflick and Paul Moorhead cultured human fetal fibroblast strains and tracked them through serialpassage. The cells grew vigorously, then slowed, then stopped dividing altogether while remaining alivepassage. The cells grew vigorously, then slowed, then stopped dividing altogether while remaining aliveand metabolically active — roughly fifty population doublings for the strains they followed. Hayflickand metabolically active, after roughly fifty population doublings for the strains they followed.called the terminal state Phase III. Crucially, the arrest travelled with the cells rather than with theHayflick called the terminal state Phase III. The arrest travelled with the cells rather than with theculture conditions: cells frozen at a given doubling level resumed at that level when thawed, which isculture conditions: cells frozen at a given doubling level resumed at that level when thawed, which ishard to explain as damage from bad medium.[^hayflick1961] A 1965 paper set out the argument athard to explain as damage from bad medium.[^hayflick1961] A 1965 paper set out the argument atlength.[^hayflick1965] Frank Macfarlane Burnet named the phenomenon the Hayflick limit in 1974.[^burnet1974]length.[^hayflick1965] Frank Macfarlane Burnet named the phenomenon the Hayflick limit in 1974.[^burnet1974]lines 83–90 → 83–907 unchanged lines not shown
> [!caution] What a dish does not show> [!caution] What a dish does not show> The limit is a property of cells in culture. Most somatic cells in a living body never approach their> The limit is a property of cells in culture. Most somatic cells in a living body never approach their> replicative capacity, and senescent cells accumulating in aged tissue arise largely through stress and> replicative capacity, and senescent cells accumulating in aged tissue arise largely through stress and> damage rather than through counting divisions. That the limit exists is not in dispute; that it sets> damage rather than through counting divisions. That the limit exists is not in dispute. The claim> the length of a human life is a much larger claim, and the evidence for it is indirect.> that it sets the length of a human life is much larger, and the evidence for it is indirect. ## WI-38 and the ownership dispute## WI-38 and the ownership dispute lines 100–107 → 100–1079 unchanged lines not shown
was settled out of court in 1981 on terms that left the ownership question undecided while permitting himwas settled out of court in 1981 on terms that left the ownership question undecided while permitting himto continue distributing the strain. A group of prominent biologists publicly criticized the handling ofto continue distributing the strain. A group of prominent biologists publicly criticized the handling ofthe case, and eighty-three of them signed a letter to *Science* arguing that the settlement terms had notthe case, and eighty-three of them signed a letter to *Science* arguing that the settlement terms had notbeen disclosed and should be.[^strehler1982] The episode is a standard reference point in arguments about title to humanbeen disclosed and should be.[^strehler1982] The episode is a standard reference point in argumentsbiological material, alongside the better-known HeLa and Moore cases.about title to human biological material, alongside the better-known HeLa and Moore cases. ## Aging, longevity and disease## Aging, longevity and disease lines 112–119 → 112–1194 unchanged lines not shown
erodes. On this account, curing the diseases would not touch aging, and studying the diseases would noterodes. On this account, curing the diseases would not touch aging, and studying the diseases would notexplain it.[^hayflick2007]explain it.[^hayflick2007] Two conclusions followed that he defended for decades. Aging is not itself a disease, so framing it asHe defended two conclusions from this for decades. Aging is not itself a disease, so framing it as oneone is a category error rather than a strategy. And because entropy is not a mechanism that can beis a category error rather than a strategy. And because entropy is not a mechanism that can betargeted, immortal biological systems cannot exist. He resisted the popular reading of the replicativetargeted, immortal biological systems cannot exist. He resisted the popular reading of the replicativelimit as a countdown that fixes the length of a human life; on his account the limit is one expression oflimit as a countdown that fixes the length of a human life; on his account the limit is one expression ofaccumulating molecular disorder rather than a clock that times a lifespan. His trade book *How and Why Weaccumulating molecular disorder rather than a clock that times a lifespan. His trade book *How and Why Welines 123–130 → 123–1303 unchanged lines not shown
researchers in the field, stating that no currently marketed intervention had been shown to slow, stopresearchers in the field, stating that no currently marketed intervention had been shown to slow, stopor reverse human aging, that some products sold on that claim were potentially harmful, and that theor reverse human aging, that some products sold on that claim were potentially harmful, and that thescience invoked to sell them was routinely misrepresented.[^olshansky2002] The statement was aimed atscience invoked to sell them was routinely misrepresented.[^olshansky2002] The statement was aimed atthe commercial anti-aging market, not at aging research, and its authors said so; it has nonethelessthe commercial anti-aging market rather than at aging research, and its authors said so; it hasbeen quoted in both directions ever since. Its central claim has not yet been overtaken: nononetheless been quoted in both directions ever since. Its central claim has not yet been overtaken: no[[dietary-supplements|supplement or marketed compound]] has since been shown in a randomized human trial[[dietary-supplements|supplement or marketed compound]] has since been shown in a randomized human trialto slow aging.to slow aging. lines 132–158 → 132–1591 unchanged line not shown
The 1961 result took a decade to be accepted and is now uncontested. It made [[cellular-senescence]] aThe 1961 result took a decade to be accepted and is now uncontested. It made [[cellular-senescence]] asubject, and the senescent cell is the target of the [[senolytics]] programme, one of thesubject, and the senescent cell is the target of the [[senolytics]] programme, one of the[[hallmarks-of-aging]], and part of the case for the [[geroscience-hypothesis]] — the proposition that[[hallmarks-of-aging]], and part of the case for the [[geroscience-hypothesis]], the proposition thataging is the shared upstream driver of chronic disease and can be slowed. Hayflick rejected thataging is the shared upstream driver of chronic disease and can be slowed. Hayflick rejected thatproposition. The field he founded is largely built on denying his conclusion while relying on hisproposition. The field he founded largely relies on his observation while denying his conclusion,observation, a tension that neither side has resolved.and neither side has resolved the tension. His disagreements with [[aubrey-de-grey]] and with the case for aHis disagreements with [[aubrey-de-grey]] and with the case for a[[longevity-dividend|dividend from slowing aging]] were public and unresolved at his death. The[[longevity-dividend|dividend from slowing aging]] were public and unresolved at his death. Thestrongest point on his side is that the ledger has not changed much: no intervention has beenstrongest point on his side is that the record has not changed much: no intervention has beendemonstrated to slow aging in a randomized human trial, [[maximum-human-lifespan|the record for verifieddemonstrated to slow aging in a randomized human trial, [[maximum-human-lifespan|the record for verifiedhuman lifespan]] has not moved since 1997, and [[compression-of-morbidity|the compression of illnesshuman lifespan]] has not moved since 1997, and [[compression-of-morbidity|the compression of illnessinto a shorter interval before death]] remains unachieved at population scale. The strongest pointinto a shorter interval before death]] remains unachieved at population scale. The strongest pointagainst it is that his thermodynamic account of aging is a minority position, that it is not obviouslyagainst him is that his thermodynamic account of aging is a minority position and not obviouslyfalsifiable, and that the mechanisms catalogued since — [[epigenetic-clock|epigenetic drift]],falsifiable, and that the mechanisms catalogued since, such as[[stem-cell-exhaustion]], [[proteostasis|failing protein quality control]] — look more like specific[[epigenetic-clock|epigenetic drift]], [[stem-cell-exhaustion]] andprocesses than like undifferentiated disorder, whatever eventually proves modifiable about them.[[proteostasis|failing protein quality control]], look more like specific processes than likeundifferentiated disorder, whatever eventually proves modifiable about them. Hayflick died at his home in California in 2024, at 96. The question he pressed hardest is the one hisHayflick died at his home in California in 2024, at 96. His opponents have yet to answer, on hisopponents have yet to answer on his terms: not whether an intervention can extend life in a mouse, butterms, the question he pressed hardest. He did not ask whether an intervention can extend life in awhat exactly it would mean to have slowed aging in a person, and what measurement would settle it. Thatmouse; he asked what exactly it would mean to have slowed aging in a person, and what measurement wouldis the problem [[aging-biomarkers|the search for validated biomarkers of aging]] exists to solve, and itsettle it. That is the problem [[aging-biomarkers|the search for validated biomarkers of aging]] existsis not solved.to solve, and it remains unsolved. ## See also## See also lines 170–176 → 171–17711 unchanged lines not shown
[^hayflick1961]: `paper` Hayflick, L. and Moorhead, P. S. "The serial cultivation of human diploid cell strains." *Experimental Cell Research*, 1961. {Human cells in culture; the doubling limit is a property of cells in a dish and was never measured in a living person.}[^hayflick1961]: `paper` Hayflick, L. and Moorhead, P. S. "The serial cultivation of human diploid cell strains." *Experimental Cell Research*, 1961. {Human cells in culture; the doubling limit is a property of cells in a dish and was never measured in a living person.}[^hayflick1965]: `paper` Hayflick, L. "The limited in vitro lifetime of human diploid cell strains." *Experimental Cell Research*, 1965.[^hayflick1965]: `paper` Hayflick, L. "The limited in vitro lifetime of human diploid cell strains." *Experimental Cell Research*, 1965.[^burnet1974]: `book` Burnet, F. M. *Intrinsic Mutagenesis: A Genetic Approach to Ageing*, 1974. {The book that named the limit; Burnet was arguing for his own mutation theory of aging, which did not survive.}[^burnet1974]: `book` Burnet, F. M. *Intrinsic Mutagenesis: A Genetic Approach to Ageing*, 1974. {The book that named the limit; Burnet was arguing for his own mutation theory of aging, which did not survive.}[^strehler1982]: `statement` Bernard L. Strehler et al. "Hayflick–NIH Settlement." *Science* 215, no. 4529 (1982): 240. {A letter to the editor signed by eighty-three scientists, not independent reporting — the signatories are arguing a position on the case, and their complaint is that the settlement terms were not public.}[^strehler1982]: `statement` Bernard L. Strehler et al. "Hayflick–NIH Settlement." *Science* 215, no. 4529 (1982): 240. {A letter to the editor signed by eighty-three scientists, not independent reporting; the signatories are arguing a position on the case, and their complaint is that the settlement terms were not public.}[^hayflick2007]: `paper` Hayflick, L. "Entropy Explains Aging, Genetic Determinism Explains Longevity, and Undefined Terminology Explains Misunderstanding Both." *PLoS Genetics*, 2007. {An argument piece, not a research report; it sets out the author's definitional case rather than testing it.}[^hayflick2007]: `paper` Hayflick, L. "Entropy Explains Aging, Genetic Determinism Explains Longevity, and Undefined Terminology Explains Misunderstanding Both." *PLoS Genetics*, 2007. {An argument piece, not a research report; it sets out the author's definitional case rather than testing it.}[^hayflick1994]: `book` Hayflick, L. *How and Why We Age*. Ballantine Books, 1994.[^hayflick1994]: `book` Hayflick, L. *How and Why We Age*. Ballantine Books, 1994.[^olshansky2002]: `paper` Olshansky, S. J., Hayflick, L. and Carnes, B. A. "Position Statement on Human Aging." *The Journals of Gerontology: Series A*, 2002. {Signed by fifty-one researchers; it addressed products sold as anti-aging treatments, not the feasibility of aging research.}[^olshansky2002]: `paper` Olshansky, S. J., Hayflick, L. and Carnes, B. A. "Position Statement on Human Aging." *The Journals of Gerontology: Series A*, 2002. {Signed by fifty-one researchers; it addressed products sold as anti-aging treatments, not the feasibility of aging research.}removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
149 lines are the same in both revisions, and 79 of them are not shown. Neither revision here is necessarily the current article — read Leonard Hayflick for the text this wiki stands behind today.